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Generation of endonuclease-resistant 
virus. Upon endonuclease cleavage of 
an essential viral gene the DNA double 
strand break can be repaired perfectly 
(A), mutated to yield a replication 
incompetent virus (B), mutated to yield 
a treatment-resistant virus (C), or the 
genome can be treated with a second 
endonuclease to prevent treatment 
resistance (D). 
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Some sneaky viruses, such as the human immunodeficiency virus (HIV), can integrate their genome 
into the host’s one and hide there for long periods of times (a phenomenon usually described as 
latency). This strategy protects them from the attacks of the immune system as well as from 
therapeutic agents. Thus far, complete eradication of such infections cannot be achieved and new 
therapeutic approaches are sought. A novel possibility consists in inactivating the viral DNA using 
enzymes that can recognize and cleave specific sequences. There are many variations of these 
enzymes including zinc finger endonucleases (ZFN), TAL effector nucleases (TALENs) and the 
CRISPR/Cas9 system. Their use presents several different challenges: the identification of all the 
sites where the virus establishes latency, the delivery of nucleases inside the cells, and the 
generation of viral mutants. Mutations can be generated through mechanisms linked to the viral 
genome replication, especially in the case of HIV, or directly upon imprecise DNA repair following 
endonuclease cleavage. 
In a study led by Ms. Harshana De Silva Feelixge and Dr. Daniel Stone from the Jerome Laboratory 
at Fred Hutch (Vaccine and Infectious Disease Division), the effects of ZFN-mediated cleavage of 
the HIV pol gene in generating mutations was evaluated. Four different ZFNs were delivered by 
adeno-associated virus vectors into cells co-transfected with a plasmid carrying a replication-
incompetent NL4-3 derived provirus (pDHIV3). ZFNs were effective in specifically cleaving HIV DNA 
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and about 10% of sequenced HIV genomes contained mutations in the sequences recognized by 
ZFN indicating a cleavage event, 30% of which were in frame, which means they could potentially 
still encode for functional proteins. Researchers consequently evaluated the effects of mutations on 
viral infectivity. To do so, they selected smaller mutations, which are more likely to encode for a 
protein retaining its function. Producer cells were transfected with plasmids carrying the mutated 
genes and subsequently the infectivity of the produced viral particles was evaluated.  Most mutants 
showed no infectivity, although one mutant retained infectivity comparable to the wild-type 
counterpart. Moreover, cleavage of this mutant sequence by its cognate ZFN was only observed 
with a much lower efficiency. Introduction of a second mutation in other conserved regions of the 
gene eliminated the infectivity of the resistant virus, therefore, the use of multiple nucleases could 
further reduce viral replication. 
A further problem that could arise from a process that introduces mutations is reduced sensitivity to 
antiretroviral drugs. Therefore, the researchers evaluated whether mutated viruses maintained their 
susceptibility to nucleotide or non-nucleotide reverse transcriptase inhibitors. None of the mutations 
induced a modification in the susceptibility to the drug. 
The study, published in the January issue of Antiviral Research, describes for the first time the 
possibility that endonuclease treatment can induce mutant viruses to retain their infectivity. "So far 
targeted endonucleases including CRISPR/Cas9 have been used as antiviral agents against EBV, 
HBV, HCV, HIV, HPV, HSV, HTLV, and JCV, but this is the first time a treatment resistant virus has 
been detected. Fortunately, we should be able to negate treatment resistance by using multiple 
endonucleases that target different regions of the viral genome" said Dr. Stone, opening the 
possibility for a safe utilization of this approach. Ms. De Silva concluded with another positive note: 
"With new endonuclease platforms like CRISPR/Cas9 we would be able to deliver a single 
endonuclease to target multiple regions and therefore, overcome resistance emerging due to 
selective pressure but also due to endonuclease therapy itself." 
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